Rongliflozin

A medication used for the treatment of type 2 diabetes

Rongliflozin is a pharmaceutical drug used in the management of type 2 diabetes mellitus. It belongs to the class of medications known as sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors), which work by preventing the reabsorption of glucose in the kidneys, thereby lowering blood sugar levels.

Mechanism of Action

Rongliflozin functions by inhibiting the SGLT2 protein in the proximal tubules of the kidney. This protein is responsible for the reabsorption of glucose from the urine back into the bloodstream. By blocking this protein, rongliflozin increases the excretion of glucose through the urine, which helps to lower blood glucose levels in patients with type 2 diabetes.

File:Rongliflozin structure.png

Chemical structure of Rongliflozin

Pharmacokinetics

Rongliflozin is administered orally and is rapidly absorbed from the gastrointestinal tract. It has a bioavailability of approximately 60-70%. The drug is metabolized primarily in the liver and is excreted mainly through the urine. The half-life of rongliflozin is approximately 12 hours, allowing for once-daily dosing.

Clinical Use

Rongliflozin is indicated for the treatment of type 2 diabetes in adults. It is often used in combination with other antidiabetic medications such as metformin or insulin to achieve better glycemic control. The drug is not indicated for the treatment of type 1 diabetes or diabetic ketoacidosis.

Side Effects

Common side effects of rongliflozin include urinary tract infections, increased urination, and hypoglycemia when used in combination with insulin or insulin secretagogues. Rare but serious side effects include ketoacidosis, acute kidney injury, and urosepsis.

Contraindications

Rongliflozin is contraindicated in patients with severe renal impairment, end-stage renal disease, or those on dialysis. It should also be used with caution in patients with a history of hypotension or electrolyte imbalances.

Related pages

• Type 2 diabetes mellitus
• Sodium-glucose co-transporter 2 inhibitors
• Metformin
• Insulin